Integrating multi-polygenic scores for enhanced prediction of antidepressant treatment outcomes in an East Asian population

Major Depressive Disorder (MDD) significantly impacts global public health, yet the effectiveness of antidepressant treatments varies widely across individuals. This study addresses an important gap in the literature by examining how multi-polygenic scores (PGSs) can improve predictions of selective serotonin reuptake inhibitor (SSRI) treatment outcomes in an East Asian population-a region where pharmacogenomic studies have been limited. We analyzed two Taiwanese cohorts: the Taipei Veterans General Hospital cohort (VGHTP, N = 177) and the National Health Research Institutes cohort (NHRI, N = 245), all receiving SSRIs. PGSs for 108 traits potentially relevant to SSRI treatment outcomes were derived from large-scale genome-wide association studies using PRS-CS and PRS-CSx, incorporating data from multiple ancestries. We combined these PGSs with demographic and clinical variables (e.g., baseline severity of depression, medication dosage) and employed generalized linear mixed models with L1-penalization (glmmLasso), as well as machine and deep learning algorithms, to identify and evaluate predictors. Our results revealed several important PGS predictors, notably related to insomnia, multisite chronic pain, and higher levels of inflammatory biomarkers, which consistently correlated with lower treatment efficacy. While the ensemble model achieved a modest area under the curve (AUC) of 0.631 for predicting responders/non-responders, integrating early improvement in depressive symptoms considerably boosted predictive accuracy (AUC = 0.859) for identifying remitters/non-remitters by week 8. These findings underscore the value of multi-PGS approaches and highlight the necessity of expanding pharmacogenomic research to non-European populations. Future studies with larger, diverse cohorts and additional biomarkers may further advance individualized therapeutic strategies and alleviate the burden of depression worldwide.

Authors

Institutions

Publication Details

Journal
Neuropsychopharmacology
Published
2025-10-28
DOI
https://doi.org/10.1038/s41386-025-02269-y
Primary Topic
Genetic Associations and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Integrating multi-polygenic scores for enhanced prediction of antidepressant treatment outcomes in an East Asian population

Kai‐Hsiang Hsu, Po‐Hsiu Kuo, C. Liu, Chia‐Lin Hsu et al.
Neuropsychopharmacology
Genetic Associations and Epidemiology
article

Integrating multi-polygenic scores for enhanced prediction of antidepressant treatment outcomes in an East Asian population

Kai‐Hsiang Hsu, Po‐Hsiu Kuo, C. Liu, Chia‐Lin Hsu, Annie Chung, Chia‐Yen Chen, Chih‐Jung Yeh, Shih‐Jen Tsai, Chiu‐Ping Fang, Yu‐Li Liu, Tzu‐Ting Chen, Kuang Lin, Jingyi Zheng, Chi-Shin Wu, S.-W. Lin
article en

Abstract

Major Depressive Disorder (MDD) significantly impacts global public health, yet the effectiveness of antidepressant treatments varies widely across individuals. This study addresses an important gap in the literature by examining how multi-polygenic scores (PGSs) can improve predictions of selective serotonin reuptake inhibitor (SSRI) treatment outcomes in an East Asian population-a region where pharmacogenomic studies have been limited. We analyzed two Taiwanese cohorts: the Taipei Veterans General Hospital cohort (VGHTP, N = 177) and the National Health Research Institutes cohort (NHRI, N = 245), all receiving SSRIs. PGSs for 108 traits potentially relevant to SSRI treatment outcomes were derived from large-scale genome-wide association studies using PRS-CS and PRS-CSx, incorporating data from multiple ancestries. We combined these PGSs with demographic and clinical variables (e.g., baseline severity of depression, medication dosage) and employed generalized linear mixed models with L1-penalization (glmmLasso), as well as machine and deep learning algorithms, to identify and evaluate predictors. Our results revealed several important PGS predictors, notably related to insomnia, multisite chronic pain, and higher levels of inflammatory biomarkers, which consistently correlated with lower treatment efficacy. While the ensemble model achieved a modest area under the curve (AUC) of 0.631 for predicting responders/non-responders, integrating early improvement in depressive symptoms considerably boosted predictive accuracy (AUC = 0.859) for identifying remitters/non-remitters by week 8. These findings underscore the value of multi-PGS approaches and highlight the necessity of expanding pharmacogenomic research to non-European populations. Future studies with larger, diverse cohorts and additional biomarkers may further advance individualized therapeutic strategies and alleviate the burden of depression worldwide.

NeuropsychopharmacologyVol. 51(2)
Biogen (United States) (US), National Yang Ming Chiao Tung University (TW), National Health Research Institutes (TW), National Taiwan University (TW), Taipei Veterans General Hospital (TW), Yale University (US), Taipei City Hospital (TW), National Taiwan University Hospital (TW), National Yunlin University of Science and Technology (TW), Auburn University (US), National Cheng Kung University (TW)
National Applied Research Laboratories, National Health Research Institutes, National Science and Technology Council
Openalex Percentile: Top 67%
Genetic Associations and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.